Zosano Pharma Corporation

Passed

Class Action Period:
February 13, 2017 - September 30, 2020

Lead Plaintiff Deadline:
December 28, 2020

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Allegations

(1) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company’s New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until December 28, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.